Optimer Pharmaceuticals



		Subscribe to RSS feed 2009 \| 2008 \| 2007 \| 2006 \| 2005 \| 2004 \| 2002 \| 2001 \| (6.4.2009) SAN DIEGO Optimer Pharmaceuticals to Present at June 2009 Investor Conferences (6.2.2009) SAN DIEGO Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin versus Vancocin in Subgroup Analyses from its Phase 3 Study for the Treatment of CDI (5.17.2009) SAN DIEGO, CA Optimer Pharmaceuticals Presents Results from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (5.7.2009) SAN DIEGO Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results (4.13.2009) SAN DIEGO Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin (3.11.2009) SAN DIEGO Optimer Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Financial Results (3.9.2009) SAN DIEGO Optimer Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference (3.5.2009) SAN DIEGO Optimer Pharmaceuticals to Raise $32.9 Million in Registered Direct Offering (3.3.2009) SAN DIEGO Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2008 Financial Results (3.2.2009) SAN DIEGO Optimer Pharmaceuticals to Accelerate European Filing of Fidaxomicin (OPT-80) (2.26.2009) SAN DIEGO Optimer Pharmaceuticals Announces Publication in Peer-Reviewed Journal about Prulifloxacins Antibacterial Activity against Infectious Diarrhea Producing Bacteria (2.24.2009) SAN DIEGO Optimer Pharmaceuticals Announces Positive Results from Second Phase 3 Study of Prulifloxacin for Infectious Diarrhea in Travelers (2.23.2009) SAN DIEGO, CA Optimer Pharmaceuticals Appoints Industry Veterans Francois-Xavier Frapaise as Chief Scientific Officer and Peter E. Grebow to its Board of Directors

(6.4.2009) SAN DIEGO

Optimer Pharmaceuticals to Present at June 2009 Investor Conferences

SAN DIEGO, CA – June 4, 2009 - Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Company will present at the following investor conferences:

8^th Annual Needham Life Sciences Conference on Wednesday, June 10, 2009 at 9:00 a.m. Eastern Time at the New York Palace Hotel in New York City.

Jefferies’ 3^rd Annual Healthcare Conference on Thursday, June 18, 2009 at 1:30 p.m. Eastern Time at the Mandarin Oriental Hotel in New York City.

Piper Jaffray Europe Conference on Tuesday, June 23, 2009 at 3:00 p.m. British Summer Time (8:00 a.m. Eastern Time) at the ANdAZ Hotel in London.

Live audio webcasts of these presentations will be accessible on the Company’s website at www.optimerpharma.com, under the investors section. Replays of these presentations will be available at the same location for 30 days following the meeting.

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin, formerly known as OPT-80, is the only antibiotic therapy currently in Phase 3 worldwide clinical development for Clostridium difficile infection. Prulifloxacin is an antibiotic which has completed two Phase 3 clinical trials for the treatment of travelers’ diarrhea, a form of infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.

Contacts

Optimer Pharmaceuticals, Inc.

Christina Donaghy, Corporate Communications Manager

John D. Prunty, Chief Financial Officer & VP Finance

858-909-0736

Porter Novelli Life Sciences

Jason I. Spark, Vice President

619-849-6005